Treloxinate

This classification denotes an anti-lipidemic agent with the molecular formula C16H12Cl2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7YA71JCD50, chemically known as 2,10-dichloro-12h-dibenzo(d,g)(1,3)dioxocin-6-carboxylic acid, methyl ester but generally known as treloxinate, which bears US NIH Compound Identifier 35678. European Medicines Agency schedules Treloxinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11231MIG. The term TRELOXINATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25 , No. 10 1971, List 11). TRELOXINATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule treloxinate under HS 29329970 and SITC 51569. As of Q4 2014, TRELOXINATE remains the US FDA Preferred Term for this commodity. Treloxinate bears US NLM identifiers UMLS ID C0076952 and NCI Concept Code C72988. SMILES: Clc1cc2Cc3c(OC(Oc2cc1)C(=O)OC)ccc(Cl)c3.